ArticleMethodsX2025
Standardized sulforhodamine b colorimetric cell proliferation assay for anticancer activity screening in educational and research laboratories.
Article in MethodsX, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Synthesis, computational studies, and biological evaluation of novel cyanoacrylamides as potential anticancer agents.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Expanding the Organoiridium Catalyst Design Space Using Sulfur-Containing Bioisosteres.Inorganic chemistry · 2026Article
- Phytochemical Characterization and Cytotoxic Potential of the Ethyl Acetate Fraction ofMolecules (Basel, Switzerland) · 2026Article
- Time-Dependent Effects of PFAS and Their Mixtures on Ovarian Epithelial Cell Proliferation and Chemotherapeutic Response.International journal of molecular sciences · 2026Article
- Therapeutic efficacy of hispidulin-loaded carboxymethyl cellulose nanoparticles against mammary carcinogenesis through ROS-mediated apoptosis and tissue remodelling.Frontiers in oncology · 2026Article
- Article
- Bacteriophage FNU1 negatesFrontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The sulforhodamine B (SRB) assay is a robust and cost-effective methods for assessing cellular proliferation and cytotoxicity in vitro. Originally designed to support drug screening efforts at the National Cancer Institute, this colorimetric assay quantifies protein content as a proxy for cell number and has proven reliable across diverse cancer cell lines. We present a fully standardized, step-by-step SRB assay protocol optimized for high-throughput application, educational accessibility, and translational relevance. Our streamlined protocol utilizes a fixed seeding density and simplified workflow, allowing for reproducible results with minimal technical expertise or specialized equipment. It has been successfully integrated into undergraduate teaching laboratories, while also supporting preclinical drug discovery efforts, including the identification of nitrosylcobalamin (NO-Cbl) as a novel anticancer agent. Key features of this protocol:•Provides an easy-to-follow format for generating reproducible cytotoxicity data in 96-well plates.•Can be used by novice researchers in teaching or early-stage discovery labs.•Suitable for scaling to support high-throughput compound screening campaigns.This accessible and validated SRB protocol has the potential to accelerate cancer research and empower future scientists at the bench.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.